• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Migraine Headache - Myth vs Facts

Slideshow

There is a good deal of misinformation available about migraine headaches. Which of these 10 statements are myth and which are fact?

  

Related Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Migraine-specific therapies belong in primary care setting, Jessica Ailani, MD
Related Content
AbbVie Announces Late Breaking Data at AAN to Support Atogepant Long-Term Safety, Efficacy for Migraine Prevention / image credit head pain ©jiris/stock.adobe.com

AbbVie Announces Late Breaking Data at AAN to Support Atogepant Long-Term Safety, Efficacy for Migraine Prevention

April 12th 2024
Article

AAN: 70% of participants reached ≥50% reduction in MMDs at weeks 13-16 that was consistent for 48 weeks in an interim analysis of a 156-week open-label trial.

Gepants for Migraine Prevention: A Perfect Fit for Primary Care

Gepants for Migraine Prevention: A Perfect Fit for Primary Care

March 30th 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with headache specialist Peter McAllister, MD.

Atogepant vs Rimegepant for Migraine Prevention: Daily Dose / image credit: ©New Africa/AdobeStock

Atogepant vs Rimegepant for Migraine Prevention: Daily Dose

April 11th 2024
Article

Your daily dose of the clinical news you may have missed.

Primary Viewpoints Episode 1: COVID-19 Impact on Migraine Management

Primary Viewpoints Episode 1: COVID-19 Impact on Migraine Management

July 20th 2020
Podcast

In episode 1 of Primary Viewpoints, migraine specialist Peter McAllister, MD, discusses how the COVID-19 pandemic has impacted his migraine patients.

©Kateryna_Kon/stock.adobe.com

Erenumab Rx Early in Episodic Migraine Found Superior to Oral Prophylactic Agents for Efficacy, Tolerability, Adherence

April 1st 2024
Article

The phase 4 APPRAISE trial found greater efficacy with erenumab after failure with 1 or 2 other preventives vs ongoing treatment with the nonspecific oral agents.

Migraine, Persistent VMS Tied to Higher Risk of CVD, Stroke: Daily Dose / image credit: ©New Africa/AdobeStock

Migraine, Persistent VMS Tied to Higher Risk of CVD, Stroke: Daily Dose

March 8th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2024 MJH Life Sciences

All rights reserved.